MYMD VS NVS Stock Comparison

Performance

MYMD
10/100

MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.

NVS
100/100

NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.

Technicals

MYMD
25/100

MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

NVS
10/100

NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

MYMD
10/100

Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.

NVS
73/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

MYMD
40/100

MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

NVS
44/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

MYMD

"Analyst Price Targets" not found for MYMD

NVS
67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.

Earnings

MYMD

"Earnings" not found for MYMD

NVS
39/100

NVS has missed earnings 5 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary

Nasdaq / MYMD

Healthcare

Biotechnology

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Novartis AG Summary

New York Stock Exchange / NVS

Healthcare

Drug Manufacturers - General

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Power up your portfolio